combretastatin has been researched along with Experimental Hepatoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhafeez, DA; Aly, OM; Mustafa, M; Nofal, AE; Shatla, IM | 1 |
| Chang, HZ; Huang, DP; Huang, TK; Jiang, XQ; Lai, SS; Tang, WJ; Wang, L; Wei, XH; Xu, XD; Yang, RM; Zou, Y | 1 |
2 other study(ies) available for combretastatin and Experimental Hepatoma
| Article | Year |
|---|---|
OMA1520 and OMA1774, novel 1,2,4-triazole bearing analogs of combretastatin A-4, inhibit hepatocellular carcinoma: Histological and immunohistochemical studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Carcinoma, Hepatocellular; Hep G2 Cells; HL-60 Cells; Humans; Liver Neoplasms, Experimental; Male; MCF-7 Cells; Molecular Docking Simulation; Rats; Triazoles | 2021 |
In vivo assessment of the vascular disrupting effect of M410 by DCE-MRI biomarker in a rabbit model of liver tumor.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Biomarkers, Tumor; Cell Line, Tumor; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Organophosphates; Rabbits; Stilbenes | 2014 |